These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1978 related articles for article (PubMed ID: 8471590)

  • 21. Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells.
    Rüttinger D; Li R; Urba WJ; Fox BA; Hu HM
    Clin Exp Metastasis; 2004; 21(4):305-12. PubMed ID: 15554386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The antitumor effect of tumor-draining lymph node cells activated by both anti-CD3 monoclonal antibody and activated B cells as costimulatory-signal-providing cells.
    Okamoto T; Harada M; Shinomiya Y; Matsuzaki G; Nomoto K
    Cancer Immunol Immunother; 1995 Mar; 40(3):173-81. PubMed ID: 7728776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes.
    Arca MJ; Krauss JC; Strome SE; Cameron MJ; Chang AE
    Cancer Immunol Immunother; 1996 May; 42(4):237-45. PubMed ID: 8665571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells.
    Ohno K; Yoshizawa H; Tsukada H; Takeda T; Yamaguchi Y; Ichikawa K; Maruyama Y; Suzuki Y; Suzuki E; Arakawa M
    J Immunol; 1996 May; 156(10):3875-81. PubMed ID: 8621926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    Shu SY; Chou T; Sakai K
    J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies.
    Li Q; Yu B; Grover AC; Zeng X; Chang AE
    J Immunother; 2002; 25(4):304-13. PubMed ID: 12142553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic administration of interleukin-12 can restore the anti-tumor potential of B16 melanoma-draining lymph node cells impaired at a late tumor-bearing state.
    Harada M; Tamada K; Abe K; Li T; Onoe Y; Tada H; Takenoyama M; Yasumoto K; Kimura G; Nomoto K
    Int J Cancer; 1998 Jan; 75(3):400-5. PubMed ID: 9455801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
    Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
    J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
    Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
    J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vivo antitumor efficacy of tumor-draining lymph node cells activated with nonspecific T-cell reagents.
    Shu S; Sussman JJ; Chang AE
    J Immunother Emphasis Tumor Immunol; 1993 Nov; 14(4):279-85. PubMed ID: 8280709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells.
    Yu J; Tian R; Xiu B; Yan J; Jia R; Zhang L; Chang AE; Song H; Li Q
    Int J Biol Sci; 2009; 5(2):135-46. PubMed ID: 19173035
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incubation of antigen-sensitized T lymphocytes activated with bryostatin 1 + ionomycin in IL-7 + IL-15 increases yield of cells capable of inducing regression of melanoma metastases compared to culture in IL-2.
    Le HK; Graham L; Miller CH; Kmieciak M; Manjili MH; Bear HD
    Cancer Immunol Immunother; 2009 Oct; 58(10):1565-76. PubMed ID: 19198835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model.
    Ito F; Carr A; Svensson H; Yu J; Chang AE; Li Q
    J Immunother; 2003; 26(3):222-33. PubMed ID: 12806276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile.
    Hu HM; Urba WJ; Fox BA
    J Immunol; 1998 Sep; 161(6):3033-41. PubMed ID: 9743368
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells.
    Mitsuma S; Yoshizawa H; Ito K; Moriyama H; Wakabayashi M; Chou T; Arakawa M; Shu S
    Immunology; 1994 Sep; 83(1):45-51. PubMed ID: 7821965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes.
    Kagamu H; Touhalisky JE; Plautz GE; Krauss JC; Shu S
    Cancer Res; 1996 Oct; 56(19):4338-42. PubMed ID: 8813119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stimulation of tumor-draining lymph node cells with superantigenic staphylococcal toxins leads to the generation of tumor-specific effector T cells.
    Shu S; Krinock RA; Matsumura T; Sussman JJ; Fox BA; Chang AE; Terman DS
    J Immunol; 1994 Feb; 152(3):1277-88. PubMed ID: 8301131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
    Aruga A; Aruga E; Cameron MJ; Chang AE
    J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2.
    Chang AE; Aruga A; Cameron MJ; Sondak VK; Normolle DP; Fox BA; Shu S
    J Clin Oncol; 1997 Feb; 15(2):796-807. PubMed ID: 9053507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 99.